Targeting SALL4 by entinostat in lung cancer

DSpace/Manakin Repository

Targeting SALL4 by entinostat in lung cancer

Citable link to this page


Title: Targeting SALL4 by entinostat in lung cancer
Author: Yong, Kol Jia; Li, Ailing; Ou, Wen-Bin; Hong, Clarice Kit Yee; Zhao, Wenxiu; Wang, Fei; Tatetsu, Hiro; Yan, Benedict; Qi, Lihua; Fletcher, Jonathan A.; Yang, Henry; Soo, Ross; Tenen, Daniel G.; Chai, Li

Note: Order does not necessarily reflect citation order of authors.

Citation: Yong, K. J., A. Li, W. Ou, C. K. Y. Hong, W. Zhao, F. Wang, H. Tatetsu, et al. 2016. “Targeting SALL4 by entinostat in lung cancer.” Oncotarget 7 (46): 75425-75440. doi:10.18632/oncotarget.12251.
Full Text & Related Files:
Abstract: The overall survival of lung cancer patients remains dismal despite the availability of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein report that SALL4 was aberrantly expressed in a subset of lung cancer patients with poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment led to impaired lung cancer cell growth. Expression profiling of SALL4-knockdown cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. Connectivity Map analysis revealed the HDAC inhibitor entinostat as a potential drug in treating SALL4-expressing cancers, and this was confirmed in 17 lung cancer cell lines. In summary, we report for the first time that entinostat can target SALL4-positive lung cancer. This lays the foundation for future clinical studies evaluating the therapeutic efficacy of entinostat in SALL4-positive lung cancer patients.
Published Version: doi:10.18632/oncotarget.12251
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search